News

DLH Awarded NIH Cancer Epidemiology and Genetics Contract

ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of…

2 years ago

Apexigen to Participate in the Brookline Capital Markets Newport Symposium

SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based…

2 years ago

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class…

2 years ago

Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will…

2 years ago

SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors

SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a…

2 years ago

Healthcare Triangle Announces $6.5 Million Private Placement

PLEASANTON, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the “Company”), a leading provider…

2 years ago

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ (“PMX”) for the Treatment of Endotoxemic Septic Shock

Breakthrough designation expected to help accelerate regulatory reviewTORONTO, July 11, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the…

2 years ago

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director…

2 years ago

Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical…

2 years ago

Opus Genetics to Present at OIS Retina Innovation Summit 2022

RESEARCH TRIANGLE PARK, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for…

2 years ago